bluuebunny/crossref_metadata_2025 huggingface dataset:
841-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes by Ethnicity and Race—ONWARDS 1–5
Authors: LINGVAY ILDIKO , BANGSGAARD KATRINE O. , DESOUZA CYRUS , FRAGÃO MARQUES MARIANA , NAVARRIA ANDREA , VIANNA ANDRE G.
Published: June 2024

Introduction & Objective: To assess, post hoc, the impact of ethnicity and race on the efficacy and hypoglycemia rates with once-weekly (OW) insulin icodec (icodec) vs once-daily (OD) basal insulin in adults with T2D.

Methods: Efficacy and safety outcomes were assessed within each trial across ethnic (Hispanic/Latino vs non-Hispanic/Latino) and race (Asian, Black/African American, White, Other) subgroups in insulin-naïve (ONWARDS [ON] 1, 3, 5) and insulin-treated (ON 2, 4) adults with T2D.

Results: Across all trials, no statistically significant interaction between treatment and subgroup for improvements in A1C were seen with icodec vs OD insulin (baseline to planned end of treatment) (Figure). Hypoglycemia rates were low in both treatment groups across ethnicities and races, precluding statistical analysis. A greater proportion of individuals in most ethnic and racial subgroups across trials achieved A1C < 7% without clinically significant or severe hypoglycemia with icodec vs OD insulin (no statistically significant treatment by subgroup interaction).

Conclusion: A1C and hypoglycemia endpoints were consistent for OW icodec vs OD insulin, irrespective of ethnicity or race.

Disclosure

I. Lingvay: Consultant; Altimmune, Astra Zeneca, Bayer, Biomea, Boehringer-Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Sanofi. Research Support; NovoNordisk, Sanofi, Mylan, Boehringer-Ingelheim. Consultant; TERNS Pharma, The Comm Group, Valeritas, WebMD, and Zealand Pharma. K.O. Bangsgaard: Employee; Novo Nordisk A/S. C. Desouza: Advisory Panel; Novo Nordisk, Bayer Inc., Madrigal Pharmaceuticals, Inc. Other Relationship; ADA/ACC Diabetes by Heart Program. Advisory Panel; Asahi Kasei. M. Fragão Marques: None. A. Navarria: Employee; Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc. A.G. Vianna: Board Member; Abbott, Lilly Diabetes, Novo Nordisk, Medtronic. Speaker's Bureau; AstraZeneca, Novo Nordisk. Research Support; Novo Nordisk, Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Research Support; Servier Laboratories.

Funding

Novo Nordisk A/S
85-OR: The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation in the United States from 2007–2022
Authors: STEPANOVA MARIA , GOLABI PEGAH , DE AVILA LEYLA , ONG JANUS , ALQAHTANI SALEH , YOUNOSSI ZOBAIR
Published: June 2024

Introduction & Objective: Type 2 diabetes (T2D) and associated non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) can negatively impact outcomes of patients with chronic liver disease (CLD). The aim of this study was to assess the impact of pre-transplant T2D on the outcomes of liver transplantations.

Method: From the Scientific Registry of Transplant Recipients (2007-2022), we selected all adults who received a liver transplant and had listing diagnosis of CLD with or without hepatocellular carcinoma (HCC). The study outcome was time to post-transplant mortality.

Results: We included 104,399 subjects (mean age 56±11 years, 66% male). Considering etiologies of CLD, 3% had chronic hepatitis B, 25% chronic hepatitis C, 20% NASH/MASH, 31% alcoholic liver disease, 22% also had HCC. Of all transplant recipients, 26% had a history of pre-transplant T2D. During follow-up (median=59 months), 27% of liver transplant recipients died, 5% had graft failure. Post-transplant mortality rates were higher in recipients with pre-transplant T2D compared to those without T2D: 10% vs. 8% at 1 year, 26% vs. 21% at 5 years, 45% vs. 37% at 10 years (all p<0.0001). In multivariate survival analysis, pre-transplant T2D was independently associated with higher risk of post-transplant mortality: aHR=1.28 [1.24-1.32]. This remained significant in CLD patients without HCC, aHR=1.30 [1.25-1.35] and those with HCC, aHR=1.23 [1.15-1.31] (all p<0.0001). Other risk factors for increased mortality included older age, male sex, black race, being on life support before transplantation and receiving a re-transplant (p<0.01). There was no association between pre-transplant T2D with an increased risk of graft failure (one-sided p>0.05).

Conclusions: About one quarter of patients receiving liver transplantation in the U.S. have T2D. The presence of pre-transplant T2D is independently associated with an increased risk of post-transplant mortality.

Disclosure

M. Stepanova: None. P. Golabi: None. L. de Avila: None. J. Ong: None. S. Alqahtani: Consultant; AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc. Z. Younossi: Consultant; Gilead Sciences, Inc., Bainan Biotech, AbbVie Inc., Bristol-Myers Squibb Company, Abbott, Novo Nordisk, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Siemens Healthcare Diagnostics, Intercept Pharmaceuticals, Inc.
866-P: Assessing the Generalizability of the FIDELIO-DKD and FIGARO-DKD Criteria to the Canadian Population with Type 2 Diabetes in a Community Endocrinology Setting
Authors: JAZDAREHEE ARIA , JAIN AKSHAY B.
Published: June 2024

Finerenone improves renal and cardiovascular outcomes in CKD and T2D, as demonstrated in the FIDELIO and FIGARO trials. While the ADA guidelines advise finerenone for residual renal risk, Canadian guidelines lack such recommendations. Previous studies established the applicability of the FIDELIO and FIGARO inclusion criteria to the US population. This study aims to assess if these criteria similarly apply to the Canadian population.

We applied the FIDELIO and FIGARO trial criteria to Canadians with T2D in a community endocrinology setting, who were already optimized for renal risk with RAAS and SGLT2 therapy.

Of 369 individuals with T2D optimized on RAAS and SGLT2 inhibitors, 99 (27%) met FIDELIO or FIGARO criteria. Population characteristics were comparable with the inclusion trials, with median age 71, mean A1c 7.7%, mean eGFR 57, median uACR 284.9 mg/g, and mean SBP 132. Our study population had a higher prevalence of prior myocardial infarction compared to those in the inclusion trials (26.2% vs 7.4% and 13.2%, p <0.05).

Despite Health Canada approval of finerenone, adoption into clinical practice remains slow. We found that 27% of individuals carry residual renal risk despite optimization. The higher proportion of patients in our study with history of cardiovascular disease emphasizes the need to implement finerenone into Canadian guidelines.

Disclosure

A. Jazdarehee: None. A.B. Jain: Advisory Panel; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Advisory Panel; Amgen Inc. Speaker's Bureau; Amgen Inc., AstraZeneca. Advisory Panel; AstraZeneca. Speaker's Bureau; Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, GSK, HLS Therapeutics, Janssen, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, Novartis, N. Advisory Panel; Bausch Healthcare, Bayer,, Dexcom, Eli Lilly, Gilead Sciences, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, PocketPills, Roche,.
875-P: GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Improves Glycemic Control as Measured by CGM in Patients with Type 2 Diabetes
Authors: NIMGAONKAR ASHISH , BRYANT CHRISTINE , FINEMAN MARK
Published: June 2024

Background: GLY-200 is an investigational oral non-absorbed polymeric drug designed to bind to and enhance the barrier function of gastrointestinal mucus as a non-invasive alternative to metabolic surgery and duodenal exclusion devices. In healthy volunteers, GLY-200 lowered glucose and increased GLP-1, PYY, and bile acids, indicating pharmacologic effects of duodenal targeting. This 14-day Phase 2 study in patients with type 2 diabetes (T2D) evaluated the safety, tolerability, and pharmacodynamic effects of GLY-200. Improvements in postprandial glucose following standardized mixed-meal challenges and progressive body weight loss were seen in GLY-200 subjects.

Methods: The Ph2 study was a randomized, double-blind, placebo (PBO)-controlled inpatient study in subjects with T2D washed off metformin, BMI 18-40. Treatments included 14 days (BID) of 2.0 g GLY-200 (N=13, BMI 31.8 ± 4.09 kg/m2, baseline HbA1c 7.18 ± 0.66%) or PBO (N=12, BMI 31.7 ± 3.17 kg/m2, baseline HbA1c 7.17 ± 0.73%). A Dexcom G6 Pro was used for continuous blood glucose measuring throughout the study (Day -7 to Day 14).

Results: GLY-200 appeared safe and well-tolerated with most AEs being GI-related. During Week 2, 4-hr pre-dose (fasting) and 4-hr post-meal (postprandial) measurements demonstrated statistically significant reductions in fasting mean weighted glucose (MWG) (p=0.05) and postprandial MWG (breakfast, p=0.07; lunch, p=0.04; dinner, p=0.01) in the 2.0 g GLY-200 group vs. PBO. There was also a statistically significant reduction in 24-hr MWG for 2.0 g GLY-200 group (Week 1: 169.20 mg/dL; Week 2: 169.82 mg/dL) compared to PBO (Week 1: 211.60 mg/dL; Week 2: 216.63 mg/dL). In the second week of treatment with 2.0 g GLY-200, the average percent time in target range was twice that compared to PBO (65.7% vs 32.2%, p=0.02).

Conclusion: As early as Week 1, subjects receiving 2.0 g GLY-200 experienced clinically relevant improvements in both fasting and postprandial glucose as measured with CGM.

Disclosure

A. Nimgaonkar: None. C. Bryant: Employee; Glyscend Inc. M. Fineman: Employee; Glyscend Inc.
881-P: Optimizing Glycemic Control in Type 2 Diabetes Using Novel Endoscopic Pulsed Electric Field Therapy—A Study of Outcomes and Predictive Factors
Authors: ABU DAYYEH BARHAM K. , SARTORETTO ADRIAN , STORM ANDREW C. , MCCOLLISTER HOWARD M. , SEVERSON PAUL A. , HOLT BRONTE , CAMERON GEORGINA , VAUGHAN RHYS , LIPHAM JOHN , EKINCI ELIF I. , O'NEAL DAVID N.
Published: June 2024

Background: Duodenal dysfunction, specifically in nutrient sensing, iron homeostasis, and inflammation is linked to Type 2 Diabetes. This study assesses Endoscopic Re-Cellularization via Electroporation Therapy (ReCET™), an outpatient procedure using non-thermal pulsed electric field to regenerate the duodenal function.

Methods: Participants (18-70 years, BMI 24-40 kg/m², HbA1c 7.5%-11.0%, on 1-4 non-insulin antidiabetics) received PEF. Primary endpoints were serious adverse events at 12 weeks, with secondary endpoints including efficacy and response predictors at 24 weeks.

Results: 71 patients (age 55, 73% male, BMI 31.7 kg/m², T2D duration 5.8 years, baseline HbA1c 8.6%) participated. Treatment groups received either low or high energy doses. No SAEs occurred. The high energy group exhibited significant glycemic improvement (-1.11 HbA1c reduction vs. -0.32 in low energy group, p=0.015) and improved Time in Range, %TBWL, HOMA-IR, Triglyceride, and Ferritin. Baseline Ferritin and HbA1c were predictors of response (figure 1). Subgroup with baseline Ferritin ≥200 and HbA1c ≥8 showed a -2.04 [95%CI -3.94, -0.14] HbA1c reduction at 24 weeks with high energy.

Conclusions: ReCET™ enhances glycemic control in T2D without SAEs, impacting weight, lipid profile, and iron metabolism. This suggests a novel mechanism complementing existing T2D treatments.

Disclosure

B.K. Abu Dayyeh: Research Support; USGI Medical, Apollo Endosurgery. Consultant; Boston Scientific Corporation, Medtronic. Other Relationship; Endogenex. Research Support; ERBE. A. Sartoretto: Research Support; Endogenex, Erbe Electromedizin GmbH. Advisory Panel; Bariatek. Consultant; Boston Scientific Corporation, Intuitive Surgical. A.C. Storm: Consultant; Intuitive Surgical, Boston Scientific Corporation, Olympus. Research Support; Apollo Endosurgery, Endogenex, Microtech. Consultant; Enterasense. Research Support; OnePass. H.M. McCollister: Consultant; Endogenex. P.A. Severson: Consultant; Endogenex. B. Holt: None. G. Cameron: None. R. Vaughan: None. J. Lipham: Consultant; Endogenex, Ethicon, Inc., Implantica. E.I. Ekinci: Advisory Panel; Lilly Diabetes. Research Support; Novo Nordisk, Boehringer-Ingelheim, Eli Lilly and Company. Board Member; Eli Lilly and Company. Advisory Panel; Abbott. Research Support; Endogenex, Versanis, AstraZeneca. D.N. O'Neal: None.
885-P: IND-Enabling Assessment of Tolerance and Safety for SAB-142—A First-in-Class Fully Human Polyclonal Antithymocyte Immunoglobulin to Delay the Progression of Type 1 Diabetes
Authors: EGLAND KRISTI A. , MAHER DIANE , SANDHURST ERIC S. , WU HUA , SAVINOV ALEXEI Y. , EZZELARAB MOHAMED , BAUSCH CHRISTOPH L. , LUKE THOMAS C.
Published: June 2024

SAB-142, a human polyclonal anti-thymocyte immunoglobulin, is currently being evaluated for safety in a Phase 1 clinical trial for Type 1 Diabetes (T1D). Previous clinical studies showed that ThymoglobulinTM, a rabbit polyclonal anti-thymocyte immunoglobulin (rATG), significantly slowed the progression of T1D. However, rATG is highly immunogenic and causes serum sickness limiting redosing over time. Our objective is to develop a safer and efficacious immunomodulatory agent to delay the progression and/or onset of T1D. Here we demonstrate the preclinical safety and tolerance of SAB-142 in Cynomolgus macaques, as well as in vitro safety and activity assays. For in vitro assays, binding of SAB-142 to human serum proteins and Glomerular Basement Membrane (GBM) antigen was assessed by ELISA. Platelet and red blood cell (RBC) binding was determined by flow cytometry and hemagglutination assays, respectively. A single dose of SAB-142 (1, 5, and 10 mg/kg), and rATG (5 mg/kg) as an active comparator, were infused intravenously to groups of 6 macaques, which were monitored for 4-weeks post-infusion. Clinical scoring was performed; blood and tissue samples were analyzed. SAB-142 bound below detection limits to human serum proteins and GBM in vitro. As compared to rATG, SAB-142 had higher platelet binding, but lower binding to RBCs. In macaques, SAB-142 and rATG were equally well tolerated, and no adverse effects were observed. All monkeys maintained normal body weight and ability to thrive. Despite reduced white blood cell counts, as expected by both reagents, no bleeding or thrombotic complications were observed post-infusion. ECG, hematology, coagulation, urine analyses and metabolic parameters were normal during and post-infusion. At the end of the study, no pathological findings were observed in native organs. Our results indicate that SAB-142 is well tolerated and should be immunomodulatory in humans.

Disclosure

K.A. Egland: None. D. Maher: Employee; SAB Biotherapeutics, Inc. E.S. Sandhurst: Employee; SAB Biotherapeutics, Inc. H. Wu: None. A.Y. Savinov: None. M. Ezzelarab: Consultant; SAB Biotherapeutics, Inc. C.L. Bausch: None. T.C. Luke: None.
888-P: Therapy Recommendation Neural Network for Comorbid Cardiometabolic Diseases
Authors: DIBNER YARON , BRANDT NICOLAS , KRENTZ ANDREW , LOZHKINA ARINA , LUSTER ALEXANDRE , PÈRE ARTHUR , JAUN ANDRÉ
Published: June 2024

Objectives: Type 2 diabetes, hypertension, and hypercholesterolemia often develop in tandem with risk factors that appear to be more than additive. This work studies early therapeutic intervention beyond the silos that are created when looking at each morbidity separately.

Methods: After reproducing national guidelines for three morbidities using a neural network, we rely on transfer learning to record real world evidence outcomes from 469,496 primary care patients to optimise therapeutic outcomes from a multi-morbidity perspective in the following 2 years. Single morbidity treatment recommendations are adequate for the majority, but are optimally complemented with a comorbid therapy for a minority. Shapley values explain differences and are used with digital twin cohorts to reject the null hypothesis for no clinical benefit over guidelines with 95% confidence.

Results: Applied retrospectively on a test set with 10,676 cardiometabolic therapy decisions, 807 comorbidity recommendations were identified, 575 with p<0.05 after testing digital twin cohorts for statistical support. Among these, diabetes therapies with two active ingredients should sometimes be complemented, either with an angiotensin receptor blocker (167) or a statin (117), in spite of not qualifying for a formal comorbid diagnosis. Apart from systolic blood pressure and ldl-c levels, we find that ethnicity plays an important role, with individuals of Asian origins being more than twice as likely to benefit from an early comorbidity intervention.

Conclusion: In this proof-of-concept study, we demonstrated that a neural network can formulate therapy recommendations beyond clinical guidelines to improve comorbid outcomes for persons with type 2 diabetes in primary care.

Disclosure

Y. Dibner: None. N. Brandt: None. A. Krentz: Research Support; Daiichi Sankyo. A. Lozhkina: None. A. Luster: None. A. Père: None. A. Jaun: None.
928-P: The SGLT2 Inhibitor Canagliflozin Ameliorates Polycystic Ovary Syndrome and Attenuates Inflammation by Reducing the Activation of NLRP3 Inflammasome
Authors: ZHANG YUQIN , CAI MEILI , DILIMULATI DILIQINGNA , ZHANG MANNA
Published: June 2024

Polycystic ovary syndrome (PCOS) is closely related to chronic low-grade inflammation and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome. The sodium-glucose cotransporter 2 (SGLT2) inhibitor reduces inflammation and attenuates the progression of PCOS. We assessed whether canagliflozin (CAN) alleviates PCOS by attenuating the NLRP3 inflammasome activation. C57BL/6 mice were treated with dehydroepiandrosterone and a high-fat diet to induce PCOS models for 21 days. Then PCOS mice were randomly divided into two groups: PCOS group and PCOS+CAN group, treated with vehicle or 25mg/kg/day CAN for 21 days by daily oral gavage. In vitro, NLRP3 inflammasome was induced by using lipopolysaccharides (LPS) and adenosine 5'-triphosphate (ATP) in mouse-primary-granulosa-cells (mpGCs), followed by CAN intervention. After CAN intervention, irregular estrous cycle and ovarian morphology with fewer corpora lutea and antral follicles, but more atretic follicles and cysts in PCOS mice were improved. Compared with PCOS group, the levels of testosterone, glucose metabolism, insulin resistance, and triglycerides were improved after the use of CAN. Immunohistochemical staining showed that levels of NLRP3 were down-regulated in the ovarian tissues of PCOS+CAN group compared to PCOS group. The mRNA and protein levels of NLRP3, the inflammasome adapter protein ASC and Caspase-1, N-terminal fragment of gasdermin D (GSDMD-N), downstream inflammatory factors IL-1β and IL-18 in PCOS+CAN group were significantly lower than those in PCOS group. In vitro, LPS+ATP-induced inflammation in mpGCs led to activation of the NLRP3 inflammasome, and this effect was prevented by the addition of CAN. These results showed that canagliflozin attenuated the reproductive and metabolic characteristics of PCOS and ameliorated inflammation by ameliorating activation of the NLRP3 inflammasome.

Disclosure

Y. Zhang: None. M. Cai: None. D. Dilimulati: None. M. Zhang: None.
933-P: Effects of Dapagliflozin and Metformin on Vascular Function in Newly Diagnosed Type 2 Diabetes—A Randomized Controlled Trial (DMVascular Study)
Authors: DALAN RINKOO , JIE CHEE YING , ZHANG XIAOE
Published: June 2024

Aims: We aim to evaluate impact of Metformin vs Dapagliflozin vs combination (Dapagliflozin/Metformin) on surrogate measures of cardiovascular risk - endothelial function, artery stiffness and carotid artery intima-media thickness (CIMT) in a 12 week, randomized controlled study.

Methods: We screened 223 participants using oral glucose tolerance test. Participants with Type 2 DM were included. Primary outcome variables were arterial stiffness (cf-PWV-Sphygmocor), endothelial function (RHI-EndoPAT), and CIMT. ANCOVA model was fitted for change from baseline, to examine drug effect on the variables adjusting for baseline and change from baseline in HbA1c. Pairwise comparisons between the treatment arms were performed.

Results: We recruited 60 participants (Age: 50.2 (8.1) years, Male 30(50%)) to Metformin (n=21), Dapagliflozin (n=18) or Metformin & Dapagliflozin (n=21). We found a statistically significant difference in CIMT between the Metformin arm and the Dapagliflozin arm (difference: 0.06; 95% CI: 0.01 - 0.11; p-value=0.03 ). The difference in cf-PWV and ln-RHI did not reach statistical significance (p>0.05) (Figure 1).

Conclusion: Initial treatment with Dapagliflozin gives a better response than Metformin for CIMT. Larger-scale longitudinal studies will clarify the potential of SGLT-2 inhibitors as initial diabetes pharmacotherapy.

Disclosure

R. Dalan: None. Y. Chee: None. X. Zhang: None.

Funding

National Medical Research Council (MOH-000014)
951-P: The t:slim X2 with Control-IQ Technology Overcomes Missed Boluses for Moderate Meals
Authors: FU LARRY , TRAHAN ALEX , MESSER LAUREL H. , CONSTANTIN ALEXANDRA
Published: June 2024

Introduction & Objective: People with diabetes frequently miss mealtime insulin boluses. The t:slim X2 pump with Control-IQ technology (CIQ) delivers automatic correction insulin, which is thought to help improve glycemia when users do not consistently bolus for meals. This study uses simulations of a virtual population representative of CIQ users to evaluate the benefits of CIQ for users who do not bolus for small or moderate meals, as compared to those on multiple daily injections (MDI).

Methods: We leveraged 500,000 user years of real-world CGM, pump, and behavior data from over 420,000 customers to develop Tandem’s Statistical Simulator (TSS). TSS includes statistical models of user and population physiologies, behaviors, aleatory uncertainty, and CIQ system components. It can be used to run in silico clinical trials on populations representative of CIQ users in the real world. The TSS was used to compare glycemic outcomes for a group of 1000 virtual users under 4 scenarios: MDI vs. CIQ when bolusing for every meal, and CIQ vs MDI when not bolusing for small/moderate sized meals (≤40g carbs).

Results: Virtual MDI subjects who bolused for every meal had a median (IQR) of 58% (26-76%) TIR and 0.9% (0.2-2.3%) TBR. These same virtual subjects using CIQ who bolused for every meal had 69% (58-79%) TIR and 0.7% (0-3%) TBR. Virtual MDI subjects who did not bolus for meals ≤40 g of carbs had a 14% (2-37%) TIR and 0.1% (0-0.8%) TBR. These same virtual subjects using CIQ had 63% (53-71%) TIR and 0.6% (0.1-1.9%) TBR under same conditions.

Conclusion: CIQ significantly improves TIR regardless of bolus scenario, but is especially effective for individuals who miss boluses for moderate meals (more than tripling TIR). This suggests that MDI users who are prone to missing boluses would benefit greatly from CIQ use even if they continued not to bolus or count carbs accurately. This further provides evidence in line with ADA guidelines 2024 that diabetes technology should be offered to everyone (and not just the “best” candidates).

Disclosure

L. Fu: None. A. Trahan: Employee; Tandem Diabetes Care, Inc. L.H. Messer: Employee; Tandem Diabetes Care, Inc. A. Constantin: Employee; Tandem Diabetes Care, Inc.

Funding

Tandem Diabetes Care
967-P: The Use of Hybrid Closed-Loop Insulin Delivery in Adolescents and Young Adults with High-Risk Acute Lymphoblastic Leukemia during Induction Chemotherapy
Authors: JOST EMILY , CHO SOOHEE , LANGE SAMANTHA , BERGET CARI , PINSKER JORDAN E. , HARTMAN LISA , FORLENZA GREGORY P.
Published: June 2024

Introduction & Objective: Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) are at risk of iatrogenic hyperglycemia during induction chemotherapy due to exposure to high dose corticosteroids and asparaginase, two cornerstones of ALL therapy. While hyperglycemia has been associated with adverse clinical outcomes, it is often underrecognized and undertreated. We evaluated the use of a hybrid closed-loop (HCL) insulin delivery system in this novel population at risk for severe hyperglycemia.

Methods: In this prospective trial, participants with newly diagnosed high-risk ALL received treatment with the Tandem t:slim X2 insulin pump with Control-IQ technology and Dexcom G6 continuous glucose monitor (CGM) during the 5-week chemotherapy induction period. The primary outcome was safety of HCL insulin delivery, as measured by hypoglycemia and adverse device events. Insulin usage and time in range (TIR) were also measured.

Results: A total of 5 participants, aged 13-18 years with no history of diabetes, received treatment with HCL insulin delivery. All participants started the system within 2 days after initiation of chemotherapy with high dose corticosteroids and prior to administration of asparaginase. Participants wore the system for a mean of 21 days and CGM for a mean of 23 days. The mean total daily insulin dose was 34.2 ± 24.9 units/day. Mean TIR was 84 ± 13% while on HCL, and mean time below range (TBR) was 0.9% ± 1.2%. One adverse event was related to bleeding at the CGM insertion site, and there were no severe hypoglycemic events.

Conclusion: The use of an HCL insulin delivery system for AYA patients with newly diagnosed ALL during induction chemotherapy met all feasibility and safety goals during this pilot trial. Rapid changes in insulin resistance caused by chemotherapy agents require close monitoring and prompt adjustments in HCL settings in this novel population.

Disclosure

E. Jost: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc. S. Cho: None. S. Lange: None. C. Berget: Speaker's Bureau; Dexcom, Inc., Insulet Corporation, embecta. J.E. Pinsker: Employee; Tandem Diabetes Care, Inc. L. Hartman: None. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc.

Funding

Tandem Diabetes and Dexcom Inc.
974-P: High Time in Closed Loop for Control-IQ Technology with New Interoperable iCGM Sensors
Authors: HABIF STEPHANIE , MUFTI SABAH , MANNING MICHELLE L. , WU KEVIN , MESSER LAUREL H.
Published: June 2024

Background: The FDA defines medical device interoperability as “the ability to safely, securely, and effectively exchange and use information among one or more devices⋯ technologies, or systems.” Interoperability helps address barriers to diabetes device use such as lack of access, high cost, and preferences for use, by offering users choice for their diabetes care.  The t:slim X2 with Control-IQ technology is the first automated insulin delivery (AID) system in the U.S. with an interoperable continuous glucose monitor (iCGM) option. In late 2023, Tandem users participated in a first access launch and remote software update of their AID system, enabling use of iCGMs including the Dexcom G7, G6, and Abbott Freestyle Libre 2 Plus (FSL2Plus). Here we report on system performance and perceptions on usefulness, and ease of use.  

Methods: 154 existing Tandem pumpers elected to update their pump software to use the Dexcom G7 or FSL2Plus integrated with their t:slim X2 pump. These users had 1+ sensor changes and ≥ 18 days of system use at time of analysis. Daily qualitative feedback from email surveys were analyzed along with back-end system performance data. 

Results: The t:slim X2 pump median time in automation was ≥92% (excluding CGM warm-up time) irrespective of CGM brand. User satisfaction was high, and primary qualitative themes included ease of use and perceptions of performance. Specifically, ease of the software update process and device pairing, as well as perceptions around system connectivity and accuracy were main contributors to positive user feedback.

Conclusion: This is a first report of people with diabetes using an AID system with multiple iCGMs in the U.S. Time in automation was high in this real-world setting, and users reported positive experiences, in line with published evidence for Control-IQ technology. An AID system with the ability to choose sensor type enables people with diabetes to optimize their device experience, and reduces barriers due to cost, access, or wearability.

Disclosure

S. Habif: Employee; Tandem Diabetes Care, Inc. S. Mufti: Employee; Tandem Diabetes Care. M.L. Manning: Employee; Tandem Diabetes Care, Inc. K. Wu: None. L.H. Messer: Employee; Tandem Diabetes Care, Inc.

Funding

Tandem Diabetes Care
976-P: Diabetes Technology Use in U.S. Hospitals
Authors: HUGHES MICHAEL S. , MORGAN MARCI , HSU LIANA , LIU YING-TING , YEH LEE MING , HANES SARAH , FIELDING-SINGH VIKRAM , HOOD KOREY K. , BUCKINGHAM BRUCE A. , LAL RAYHAN
Published: June 2024

Introduction: Outpatient use of diabetes devices, including continuous glucose monitors (CGM), insulin pumps, and automated insulin delivery (AID) is increasing, and guidelines suggest continuation during hospitalization, despite off label use and limited guidance. We conducted an online survey to understand current real world diabetes technology continuation and use in hospital.

Methods: From May-Nov 2023, a survey was distributed via diabetes-related networks and social media. Eligible participants were living with or caring for someone with diabetes who experienced a hospitalization in the prior year and used a CGM and/or insulin pump at that time.

Results: Of 540 responses, 283 were excluded for ineligibility, incompleteness, or duplication. The remaining cohort (N=258) was mostly ≥18 years (92%), female (69%), white (94%), privately insured (62%), and had type 1 diabetes (93%). Hospitalizations occurred in 45 US states, commonly for surgery (32%), glycemia (20%), or infection (12%). A majority used their devices for ≥90% of their stay (fig). Among inpatient AID users (n=133), 74% felt glucoses were well-controlled vs. 49% of those who discontinued AID (n=33) (p=0.005).

Conclusion: Outpatient diabetes technology is commonly used in hospital glucose management, with users reporting more in target glycemic control. Further research should explore hospital implementation and how effectiveness and operational demands compare to traditional methods.

Disclosure

M.S. Hughes: Consultant; Dexcom, Inc. M. Morgan: None. L. Hsu: None. Y. Liu: None. M. Lee: None. S. Hanes: None. V. Fielding-Singh: None. K.K. Hood: Consultant; Cecelia Health, Sanofi. B.A. Buckingham: Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Arecor. R. Lal: Consultant; Abbott, Adaptyx Biosciences, Biolinq, Capillary Biomedical, Inc., Deep Valley Labs, Gluroo, PhysioLogic Devices, Portal Insulin, Tidepool. Advisory Panel; Lilly Diabetes.

Funding

National Institutes of Health (5K12DK122550, 1K23DK122017, T32DK007217, P30DK116074)
986-P: Identifying Patterns of Glycemic Control from Wearable Device Data
Authors: OKUNO TOMOKI , SORT LUCAS , MACWAN SHARON , ZHOU HUA , MILLER DONALD R. , NORMAN GREGORY J. , REAVEN PETER , ZHOU JIN
Published: June 2024

Introduction & Objective: To identify temporal patterns of glucose control measured by continuous glucose monitoring (CGM) devices for type 1 and type 2 diabetes (T1D and T2D) patients in Veterans Affairs Healthcare System.

Methods: Observational study using Dexcom CGM device data linked with patients' electronic health records from 2015-2020 to identify temporal and regional patterns of glycemic control.

Results: Using a cohort of 785 T1D and 1,466 T2D patients and their 1,551,644 CGM readings over nearly 3-years, we found that glycemic control deteriorated significantly during weekends. Average glucose differed between Sundays (highest) and Wednesdays (lowest) by 2.7mg/dL (Figure). Additionally, time-in-range (between 70 mg/dL and 180 mg/dL) and time-above-range (time above 180 mg/dL) showed similar temporal patterns. We also observed seasonal variations in glycemic trends, with patients having worse glycemic control from October to February and better control from April to August. The average glucose difference between April (lowest) and December (highest) was 4mg/dL and varied regionally, with these patterns accentuated in the Northeast compared to the Southwest. These patterns were generally similar in both T1D and T2D patients.

Conclusions: Identifying and understanding these real-world glucose fluctuations may help patients and providers better manage overall glucose control.

Disclosure

T. Okuno: None. L. Sort: None. S. Macwan: None. H. Zhou: None. D.R. Miller: None. G.J. Norman: Employee; Dexcom, Inc. P. Reaven: Research Support; Dexcom, Inc. J. Zhou: None.

Funding

This work was supported by the Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development. Additional support was received from the National Institutes of Health R01-067690 and 5R01-094775 to P.D.R., and the American Diabetes Association to P.D.R.; J.J.Z was supported by NIH (K01DK106116, R21HL150374, R01HG006139), National Science Foundation (DMS-2054253, IIS-2205441).
Fragment size of lateral Hoffa fractures determines screw fixation trajectory: a human cadaveric cohort study
Authors: Peez Christian , Zderic Ivan , Deichsel Adrian , Lodde Moritz , Richards R Geoff , Gueorguiev Boyko , Kittl Christoph , Raschke Michael J , Herbst Elmar
Published: June 2024

Background and purpose: Recommendations regarding fragment-size-dependent screw fixation trajectory for coronal plane fractures of the posterior femoral condyles (Hoffa fractures) are lacking. The aim of this study was to compare the biomechanical properties of anteroposterior (AP) and crossed posteroanterior (PA) screw fixations across differently sized Hoffa fractures on human cadaveric femora.Patients and methods: 4 different sizes of lateral Hoffa fractures (n = 12 x 4) were created in 48 distal human femora according to the Letenneur classification: (i) type I, (ii) type IIa, (ii) type IIb, and (iv) type IIc. Based on bone mineral density (BMD), specimens were assigned to the 4 fracture clusters and each cluster was further assigned to fixation with either AP (n = 6) or crossed PA screws (n = 6) to ensure homogeneity of BMD values and comparability between the different test conditions. All specimens were biomechanically tested under progressively increasing cyclic loading until failure, capturing the interfragmentary movements via motion tracking.Results: For Letenneur type I fractures, kilocycles to failure (mean difference [∆] 2.1, 95% confidence interval [CI] –1.3 to 5.5), failure load (∆ 105 N, CI –83 to 293), axial displacement (∆ 0.3 mm, CI –0.8 to 1.3), and fragment rotation (∆ 0.5°, CI –3.2 to 2.1) over 5.0 kilocycles did not differ significantly between the 2 screw trajectories. For each separate subtype of Letenneur type II fractures, fixation with crossed PA screws resulted in significantly higher kilocycles to failure (∆ 6.7, CI 3.3–10.1 to ∆ 8.9, CI 5.5–12.3) and failure load (∆ 275 N, CI 87–463 to ∆ 438, CI 250–626), as well as, less axial displacement from 3.0 kilocycles onwards (∆ 0.4°, CI 0.03–0.7 to ∆ 0.5°, CI 0.01–0.9) compared with AP screw fixation.Conclusion: Irrespective of the size of Letenneur type II fractures, crossed PA screw fixation provided greater biomechanical stability than AP-configured screws, whereas both screw fixation techniques demonstrated comparable biomechanical competence for Letenneur type I fractures. Fragment-size-dependent treatment strategies might be helpful to determine not only the screw configuration but also the surgical approach.
ÀS MARGENS DO RIO URUGUAI: A PERCEPÇÃO AMBIENTAL DOS PESCADORES DE URUGUAIANA/RS
Authors: Stefanello Cristiano Miguel , Silva Renata Colbeich da , Querol Marcus Vinicius Morini
Published: June 2024

Compreender a relação entre o indivíduo e o meio ambiente que o cerca é crucial, e a percepção ambiental desempenha um papel fundamental nesse entendimento. Em um estudo realizado com pescadores artesanais da Associação de Pescadores Artesanais e da Colônia de Pescadores Z9, em Uruguaiana, RS, investigou-se a percepção ambiental desses pescadores, que se baseia em conhecimentos tradicionais. O objetivo era avaliar os impactos das atividades locais e sua relação com os processos ambientais. O rio Uruguai, localizado na parte oeste do Rio Grande do Sul, desempenha um papel fundamental no abastecimento hídrico, na agricultura e na fonte de renda da população local. Os dados foram coletados por meio de questionários aplicados a 49 pescadores, juntamente com observações participantes, visando compreender a história de uso e a situação ambiental do rio Uruguai. O estudo também buscou traçar a percepção ambiental e a sensibilidade da comunidade em relação ao tema. Apesar do baixo desenvolvimento socioeconômico da comunidade, cuja atividade pesqueira é essencialmente de subsistência, os resultados mostraram que os pescadores possuem um bom entendimento sobre o impacto das atividades humanas no ambiente. No entanto, essa percepção ainda não tem sido suficiente para promover um manejo adequado dos recursos locais.
AUTOMATING COMPUTATIONS FOR ELECTRIC CIRCUIT ANALYSIS WITH LABVIEW
Authors:   Lviv Politecnic National University, Karpa Mykhailo , Betsyl Vitalii ,   Lviv Politecnic National University
Published: June 2024

The article considers the application of the theory of the complex variable function employing the LabVIEW graphical programming environment for automating the calculation of electric circuits. The software products have been created to implement the method of constructing the matrix of the system of linear algebraic equations by inspection for both the mesh current method and nodal potential method in electric circuits of direct and alternating current and voltage using a graphical programming environment, except for circuits with dependent sources. All developed programs can be converted into .exe files, with subsequent utilization on computers that do not have a program environment installed. These software solutions can help lecturers quickly generate solutions for new assignments, saving valuable time. Students can utilize these software products for self-control, further reducing their workload.
Karakterisasi Molekuler Tumbuhan Sidingin (Kalanchoe sp.) Asal Riau Menggunakan Empat Penanda Barkode DNA
Authors: Herman
Published: June 2024

Sidingin (Kalanchoe sp.) merupakan tumbuhan sukulen dari famili Crassulaceae yang tumbuh liar namun memiliki beberapa manfaat sebagai tumbuhan obat. Sidingin asal Riau belum dapat ditentukan nama spesiesnya. Penentuan nama spesies tumbuhan dapat dilakukan menggunakan beberapa barkode DNA, seperti matK, rbcL, dan ITS. Penelitian barkoding DNA pada sidingin asal Riau belum pernah dilakukan. Penelitian ini bertujuan menganalisis empat barkode DNA pada tumbuhan sidingin (Kalanchoe sp.) asal Riau, yaitu ITS, trnL-trnL-trnF intergenic spacer (IGS), ndhC-trnV IGS, dan rpl16 intron. Pada penelitian ini telah diperoleh sekuens DNA untuk ITS, trnL-trnL-trnF IGS, ndhC-trnV IGS, dan rpl16 intron dengan panjang basa secara berturut-turut 662 pb, 909 pb, 949 pb, dan 944 pb. Keempatnya telah didaftarkan dengan nomor registrasi, secara berturut-turut, MW297180, MW297177, MW297178, dan MW297179. Komposisi nukleotida pada ITS berbeda dengan ketiga barkode DNA lainnya. Tidak ada aksesi di GenBank yang memiliki kemiripan 100% dengan sidingin sehingga nama spesies dari sidingin belum dapat ditentukan. Variasi nukleotida paling sedikit dijumpai pada daerah trnL-trnL-trnF IGS (9,65%) dengan jumlah mutasi subtitusi dan indels relatif mirip. Namun uniknya, nukleotida kritis yang merupakan nukleotida penciri  paling banyak dijumpai pada daerah trnL-trnL-trnF IGS (1,41%). Kesimpulan, barkode DNA trnL-trnL-trnF IGS dapat digunakan untuk mengidentifikasi tumbuhan sidingin dibandingkan ketiga sekuens lainnya yang diteliti.
Ideen und Innovationen für die Mobilität der Zukunft
Authors: Doll Claus
Published: June 2024

Mit dem Deutschen Mobilitätspreis verfolgen die Initiative „Deutschland – Land der Ideen“ und das Bundesministerium für Verkehr und digitale Infrastruktur das Ziel, die Bedeutung und das Potenzial digitaler Lösungen im Hinblick auf Mobilität aufzuzeigen. Mobilitätsexperten und am Thema interessierte Privatpersonen erhalten die Chance, ihre innovativen Projekte und Ideen einer breiten Öffentlichkeit zu präsentieren. Dr. Claus Doll, Leiter des Geschäftsfeldes Mobilität am Fraunhofer-Institut für System- und Innovationsforschung und Jurymitglied des Deutschen Mobilitätspreises, analysiert die Ergebnisse des Wettbewerbsjahres 2016 und leitet zentrale Trends ab.
Verkehrssystemforschung am DLR - Mobil in Deutschland 2040
Authors: Seum Stefan , Goletz Mirko , Kuhnimhof Tobias
Published: June 2024

Szenarien zukünftiger Entwicklungen des Verkehrssystems leisten einen wichtigen Beitrag zur Unterstützung von Entscheidungsprozessen. Das ist auch das Ziel der DLR-Szenarien im Projekt Verkehrsentwicklung und Umwelt (VEU). Für die Entwicklung von Szenarien stehen verschiedene methodische Ansätze zur Verfügung. Im ersten Teil des Beitrags wurden die Vor- und Nachteile erörtert und das Vorgehen im Rahmen der VEU-Szenarien dargestellt. Der vorliegende zweite Teil des Beitrags präsentiert die Storylines der entwickelten VEU-Szenarien.
Verkehrsträger müssen voneinander lernen
Authors: Eck Florian
Published: June 2024

Der Mobilitätsstandort Deutschland liegt bei der Entwicklung autonomer Systeme weltweit im Spitzenfeld. Entgegen allen Unkenrufen haben Industrie und Forschung im traditionell starken Bereich der Deutschen, dem Mobilitätssektor, enorme Fortschritte bei der Automatisierungstechnik erzielt. Ein Kommentar von Dr. Florian Eck, Stellvertretender Geschäftsführer Deutsches Verkehrsforum.
Automatisiertes Fahren im Mobilitätssystem
Authors: Dörr Heinz , Marsch Viktoria , Romstorfer Andreas
Published: June 2024

Digitalisierung und Automatisierung bemächtigen sich der Mobilität als Daseinsbedürfnis und des Verkehrssystems als dienende Infrastruktur. Die Ausrüstung der Verkehrsmittel, vor allem der Kraftfahrzeuge, schafft veränderte Bedingungen für die Ausübung der Mobilität durch die Bevölkerungsgruppen in ihren Lebensräumen. Nutzen und Nachteile sind daher aus deren Blickwinkel in Wechselwirkung mit den fahrzeugseitigen Automatisierungstechnologien, die teilweise oder gänzlich ein fahrerloses Bewegen der Fahrzeuge im Verkehrsnetz ermöglichen werden, zu beleuchten.
Wie hoch sind die realen Emissionen von Diesel-PKW wirklich?
Authors: Becker Udo , Schmidt Wolfram
Published: June 2024

Es dürfte seit einigen Jahren bekannt sein: Die europäischen Städte haben an verkehrlich hochbelasteten Stellen ein Luftqualitätsproblem, insbesondere bei Partikel- und Stickstoffoxid-Immissionen. Dafür sind die Emissionen aus Fahrzeugen mit Dieselmotoren, vor allem auch aus Diesel-PKW, maßgeblich mitverantwortlich. Wie kam es zur heutigen Situation – und welche Lehren sind daraus zu ziehen?
Zügig die IT-Landschaft im Nahverkehr absichern
Authors: Schrettle Barbara
Published: June 2024

Beim Personennahverkehr läuft im Hintergrund eine komplexe IT-Infrastruktur, die vor Hackerangriffen geschützt sein muss. Damit dieses Sicherheitsziel nicht in Gefahr gerät, hat sich ein führender deutscher Nahverkehrsanbieter an Axians IT Security gewandt. Die IT-Sicherheitsexperten implementierten die Lösung „SecurityCenter“ von Tenable. Eine kontinuierliche Netzwerküberwachung sowie Vulnerability Management befähigen das Verkehrsunternehmen nun dazu, die gesamte IT-Umgebung transparent zu machen. So lassen sich Sicherheitslücken schnell identifizieren und sofort Abwehrmaßnahmen ergreifen.
Nutzung satellitenbasierter Ortung als sicherer und zugelassener Ortungssensor im Schienenverkehr
Authors: Manz Hansjörg
Published: June 2024

Um die Interoperabilität im europäischen Schienenverkehr zu ermöglichen, wird ETCS zunächst auf den transeuropäischen Korridoren implementiert. Jedoch existieren zahlreiche Nebenstrecken, die teilweise von einer Stilllegung bedroht sind. Sowohl zur effizienten Zugsicherung auf Nebenstrecken als auch für ETCS eignet sich die satellitenbasierte Ortung als sichere Sensorik. Dieser Artikel befasst sich im Überblick mit der Nutzung satellitenbasierter Ortung im Schienenverkehr.
Funktionalisierung der Straßenverkehrsinfrastruktur
Authors: Oeser Markus , Kemper Dirk , Fazekas Adrian , Klee Phillip-Armand , Renken Lukas
Published: June 2024

Straßen werden derzeit hauptsächlich als Flächen zur Abwicklung des Güter- und Personenverkehrs genutzt, Funktionen zur Unterstützung der Elektromobilität, des hochautomatisierten Fahrens oder der individuellen Verkehrsbeeinflussungen sind kaum integriert. Im Artikel werden hierzu technische Lösungsansätze vorgestellt und deren Potentiale kurz umrissen. Fokussiert wird auf Ansätze zur straßeninfrastrukturintegriert en Verkehrsdatenerzeugung, zur Verkehrsbeeinflussung sowie zur Energiegewinnung und -übertragung.
Verlässliche Adaptive Software-Architekturen im Auto
Authors: Weiß Gereon
Published: June 2024

Durch die zunehmende Automatisierung bis hin zum autonomen Fahren verändern sich auch die elektrisch-elektronischen (E/E) Architekturen sowie die Anforderungen an die Funktionalität von Fahrzeugen. Das hat zur Folge, dass Software-Architekturen eine zunehmende Flexibilität aufweisen und gleichzeitig eine erhöhte Zuverlässigkeit garantieren müssen.
the intelligent railway system theory
Authors: Tokody Dániel , Flammini Francesco
Published: June 2024

Digitalisation of the railway industry and its future challenges were among the main topics at the 2016 International Trade Fair for Transport Technology (InnoTrans). Digitalisation presents a new opportunity for the future of the railway industry. The digital age and the digital development of transportation also contribute to the competitiveness of the European rail industry. In Hungary, we have been conducting scientific research with the purpose of developing an intelligent railway system within the intelligent transport system since 2014. In 2017, the consortium partners will launch a research and development project worth over EUR 9.5 million. The primary goal is to build an economical branch line railway system that benefits from the advantages of IP-based technologies and artificial intelligence.
Entwicklung eines Bewertungsmodells für die Fahrradfreundlichkeit von Stadtteilen am Beispiel Berlin
Authors: Hausigke Sven
Published: June 2024

Erhebungsmethoden in der Evaluation des Radverkehrs nutzen kaum das verfügbare Open-source-Datenangebot, um raumübergreifende, vergleichende Analysen zur Situation der Fahrradfreundlichkeit zu erheben. Im Rahmen der Untersuchung für ein quantitatives Bewertungsmodell zur Messung der Fahrradfreundlichkeit (beeinflussende Faktoren zur Nutzung des Rads) wurden beeinflussende Faktoren identifiziert, Quellen benannt, Bewertungen der Bedeutsamkeit im Modell durchgeführt und Skalierungen durchgefüahrt, um am Beispiel Berlin demonstrativ auf Ebene von Planungsräumen erste Erkenntnisse dazu zu sammeln.
Entwicklung eines Kernnetzes für Oberleitungs-LKW
Authors: Bernecker Tobias , Hacker Florian , Neubauer Gregor , Kühnel Sven , Boysen Jens , Schubert Markus
Published: June 2024

Der Beitrag befasst sich mit der modellgestützten Entwicklung eines Kernnetzes für den Einsatz von Oberleitungs-LKW (O-LKW) in Deutschland. Beschrieben werden die Ermittlung geeigneter Strecken sowie deren Verknüpfung zu einem denkbaren Netz. Auf Basis einer Rangliste von Netzabschnitten, die für eine Elektrifizierung besonders interessant erscheinen, werden dabei zwei verschiedene Ausbaustrategien und ein mögliches Zielnetz von rund 4250 km Länge vorgestellt sowie anhand verschiedener Kennzahlen (u. a. der Fahrleistung) vergleichend beurteilt.
Vehicle Stock Modelling: A new approach
Authors: Heinrich Lea , Segel Felix D. , Schulz Wolfgang H.
Published: June 2024

Forecasting mobility and travel demand with the aid of dedicated model-based approaches is a recognized method to deal with challenges related to urban transport planning as well as the fulfilment of political goalsetting. Nevertheless, even if for the transport segment a large variety of forecasting models exists, the specification on limited purpose forecasts doesn’t meet the requirements of integrated, realistic, longterm planning measures. The presented vehicle stock model as a generic, multi-purpose-oriented forecast tool closes this gap with a new, time series analysis based approach.